Our Programs


Middle East Middle East Respiratory Syndrome (MERS) is an emerging viral disease caused by Middle East Respiratory Syndrome Coronavirus (MERS-CoV) that affects the respiratory system with symptoms of fever, cough and shortness of breath. About 3-4 out of every 10 patients reported with MERS have died.

The disease was first reported in Saudi Arabia in September 2012 although retrospective investigations later identified the first known cases of MERS occurred in Jordan in April 2012.  Currently all cases of MERS have been linked through travel to or residence in countries in and near the Arabian Peninsula. The largest known outbreak of MERS outside the Arabian Peninsula occurred in the Republic of Korea in 2015, which was associated with a traveler returning from the Arabian Peninsula.

Currently there is no vaccine to prevent MERS-CoV infection.  In late 2015, IVI launched a MERS Program with support from Samsung and the South Korean Ministry of Health & Welfare.  The support from Samsung is a three-year grant to accelerate the development of MERS vaccines, with the aim of having two MERS vaccines demonstrated to be safe and immunogenic in Phase II trials conducted in South Korea, and that can be deployed in clinical efficacy trials at possible outbreak sites.  IVI will partner with two vaccine manufacturers on early-stage clinical development of their MERS vaccine candidates by providing technical and financial support, as well as support in project management and coordination.